X

Trial Profile

Phase II Study of Weekly Genexol-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Gemcitabine
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use
Sponsors Samyang Biopharmaceuticals Corporation

Most Recent Events

06 Jun 2023 Results (n=32; Between January 2016 and February 2022) assessing the efficacy and safety of the weekly combined chemotherapy with GPM and gemcitabine in patients with recurrent and metastatic adenocarcinoma of the pancreas, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
16 Apr 2018 Planned End Date changed from 1 Feb 2018 to 1 Dec 2019.
16 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com